Please login to the form below

Not currently logged in

Janssen launches Stelara in the UK for adolescents

Psoriasis drug now available for younger patients
Janssen Logo

Janssen has launched Stelara in the UK as a treatment option for adolescents with moderate-severe plaque psoriasis.

The launch follows the European Commission's approval of Stelara (ustekinumab) in June this year, which was based on data from the phase III CADMUS trial.

This showed that after 12 weeks patients aged 12 to 17 years treated with Stelara had much greater improvement in their psoriasis compared to those on placebo.

Dr Rozlyn Bekker, medical director at Janssen UK, said: “The CADMUS study has shown that ustekinumab is an efficacious treatment option that can significantly improve psoriasis symptoms and lessen its impact on quality of life in young people aged 12 and over.”

Stelara is an interleukin (IL)-12 and IL-23 antagonist and is approved for those who have not responded to other systematic therapies such as ciclosporin, methotrexate or psoralen plus ultraviolet A (PUVA).

Dr Anthony Bewley of Royal London Hospital, said: “Ustekinumab is an innovative biologic which, we know from recent trials, can positive impact the lives of younger people with psoriasis.“

Ustekinumab has been used in adults for a number of years and we know it has been beneficial in the management of adult psoriasis, so to have the full data for the use of this medication in younger people is a great step forward.”

Plaque psoriasis is a chronic autoimmune disease affecting up to 2% of the population during childhood and adolescence equating to around 40,000 children.

It is characterised by patches of thick, red or inflamed skin covered with plaques.  

Article by
Nikhil Patel

15th September 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Latest intelligence

Australian Flu and the dilemma of naming diseases
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....